Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

NIZATIDINE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (A02B, A02BA) — coverage varies; not interchangeable

  • Cimetidine (Cimetidine): general benefit, Not a benefit
  • Famotidine (Pepcid): general benefit, Not a benefit
  • Ranitidine (Zantac): general benefit, Not a benefit
  • Misoprostol (Cytotec): general benefit, Not a benefit
  • Pantoprazole (Tecta): general benefit
  • Rabeprazole (Pariet): general benefit

7 more in the class list below

Axid · DIN 00778338 · 150mg · capsule

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Axid · DIN 00778338 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 2013-09-26 · brand AXID · ATC A02BA04 NIZATIDINE · form Capsule · route Oral · ingredients NIZATIDINE 150 MG · company Pendopharm division of pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Axid: Formulary list price $0.9047/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9047 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8915 · Verify on the e-Formulary ↗ (DIN 00778338)

Source record
DIN 00778338: Axid Raw flags: chronicUseMed=Y, sec3=Y Item: 564000027; group id 686; item number 1706; lccId None; manufacturer id PEN Source form: Cap; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.9047; ministry $0.9047 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00778338 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8915
Shortage status: resolved shortage (ended 2024-11-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00778338
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Axid · DIN 00778346 · 300mg · capsule

General benefitDormant since 2017-08-03 · checked 2026-09-02 · What does dormant mean?
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Axid · DIN 00778346 Manufacturer: Pharmel Inc.; listing date 1996-10-01 Health Canada: Dormant since 2017-08-03 · brand AXID · ATC A02BA04 NIZATIDINE · form Capsule · route Oral · ingredients NIZATIDINE 300 MG · company Pendopharm division of pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Axid: Formulary list price $1.5206/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.5206 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8916 · Verify on the e-Formulary ↗ (DIN 00778346)

Source record
DIN 00778346: Axid Raw flags: chronicUseMed=Y, sec3=Y Item: 564000028; group id 686; item number 1707; lccId None; manufacturer id PHE Source form: Cap; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.5206; ministry $1.5206 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00778346 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8916
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00778346
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2017-08-03 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

LANSOPRAZOLE & CLARITHROMYCIN & AMOXICILLIN

· 2 products · Listed, not a benefit (1), Limited Use, codes 306, 307 (1) · strengths: 30mg & 500mg & 500mg · Tab/Cap Pk

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS AXID (nizatidine capsules) is indicated for:  the treatment of conditions where a controlled reduction of gastric acid secretion is required such as for ulcer healing and/or pain relief: acute duodenal ulcer, acute benign gastric ulcer, gastroesophageal reflux disease and prophylactic use in duodenal ulcer. 1.1 Pediatrics Pediatrics (under 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use . 1.2 Geriatrics Geriatrics (over 65 years of age): Evidence from clinical studies and experience do not suggest that use in the geriatric population is associated with differences in safety or effectiveness . Age alone is not an important factor in determining the disposition of nizati dine; however elderly patients may have reduced renal function. See 4 DOSAGE AND ADMINISTRATION; 7.4 WARNINGS AND PRECAUTIONS, Geriatrics; and 10.3 CLINICAL PHARMACOLOGY, Pharmacokinetics, Elimination . https://pdf.hres.ca/dpd_pm/00062205.PDF PM date: July 20, 2021 Source product: AXID; DIN 00778338; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)